RecruitingPhase 2NCT05201469

VIBRANT: VIB4920 for Active Lupus Nephritis

A Phase 2a Randomized Placebo-Controlled Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis (ITN091AI)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment

74 participants

Start Date

May 16, 2022

Study Type

INTERVENTIONAL

Conditions

Lupus Nephritis

Summary

This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo for VIB4920 and a drug called VIB4920 for people with lupus nephritis. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVIB4920

Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone

DRUGPlacebo for VIB4920

Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone

Locations(17)

University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology

La Jolla, California, United States

UCLA Medical Center: Division of Rheumatology

Los Angeles, California, United States

of California, Irvine School of Medicine Division of Rheumatology

Orange, California, United States

University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center

San Francisco, California, United States

University of Colorado School of Medicine: Division of Rheumatology

Aurora, Colorado, United States

Yale University School of Medicine: Section of Rheumatology

New Haven, Connecticut, United States

University of Miami Miller School of Medicine: Nephrology & Hypertension Division

Miami, Florida, United States

Emory University School of Medicine: Division of Rheumatology

Atlanta, Georgia, United States

University of Chicago, Department of Medicine: Rheumatology

Chicago, Illinois, United States

University of Michigan

Ann Arbor, Michigan, United States

Washington University School of Medicine in St. Louis: Division of Nephrology

St Louis, Missouri, United States

Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases

Manhasset, New York, United States

Hospital for Special Surgery, New York: Division of Rheumatology

New York, New York, United States

Columbia University Medical Center: Department of Medicine, Division of Rheumatology

New York, New York, United States

Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology

Hershey, Pennsylvania, United States

Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology

Philadelphia, Pennsylvania, United States

University of South Carolina

Charleston, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05201469

Related Trials

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

NCT0761121415 locations

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

US Zamto-cel Autoimmune Diseases

NCT067088451 location

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

NCT0655726519 locations

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198101 locations